D-Cyclins Repress Apoptosis in Hematopoietic Cells by Controlling Death Receptor Fas and Its Ligand FasL  by Choi, Yoon Jong et al.
Developmental Cell
ArticleD-Cyclins Repress Apoptosis in Hematopoietic Cells
by Controlling Death Receptor Fas
and Its Ligand FasL
Yoon Jong Choi,1,2 Borja Saez,3,4,5 Lars Anders,1,6 Per Hydbring,1,2 Joanna Stefano,1,2 Nickolas A. Bacon,1,2
Colleen Cook,3,4,5 Ilona Kalaszczynska,1,9 Sabina Signoretti,8 Richard A. Young,6,7 David T. Scadden,3,4,5
and Piotr Sicinski1,2,*
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
2Department of Genetics, Harvard Medical School, Boston, MA 02115, USA
3Center for Regenerative Medicine and Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA
4Harvard Stem Cell Institute, Cambridge, MA 02138, USA
5Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA
6Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
7Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
8Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115, USA
9Present address: Department of Histology and Embryology, Medical University of Warsaw, 02-004 Warsaw, Poland
*Correspondence: peter_sicinski@dfci.harvard.edu
http://dx.doi.org/10.1016/j.devcel.2014.06.015SUMMARY
D-type cyclins (D1, D2, and D3) are components of
the mammalian core cell-cycle machinery and func-
tion to drive cell proliferation. Here, we report that
D-cyclins perform a rate-limiting antiapoptotic func-
tion in vivo.We found that acute shutdown of all three
D-cyclins in bone marrow of adult mice resulted in
massive apoptosis of all hematopoietic cell types.
We demonstrate that adult hematopoietic stem cells
are particularly dependent on D-cyclins for survival
and that they are especially sensitive to cyclin D
loss. Surprisingly, we found that the antiapoptotic
function of D-cyclins also operates in quiescent he-
matopoietic stem and progenitor cells. Our analyses
revealed that D-cyclins repress the expression of the
death receptor Fas and its ligand, FasL. Acute abla-
tion of D-cyclins upregulated these proapoptotic
genes and led to Fas- and caspase 8-dependent
apoptosis. These results reveal an unexpected func-
tion of cell-cycle proteins in controlling apoptosis in
normal cell homeostasis.
INTRODUCTION
The mammalian core cell-cycle machinery is composed of
cyclins and their associated cyclin-dependent kinases (Cdks).
Cyclin-Cdk complexes phosphorylate several cellular pro-
teins, thereby driving cell-cycle progression (Malumbres and
Barbacid, 2009). Among the cell-cycle regulators, D-type
cyclins have received particular attention, due to their very
frequent involvement in the pathogenesis of human cancers
and their role as oncogenes (Deshpande et al., 2005; Fu
et al., 2004).DevelopThe family of mammalian D-type cyclins is composed of three
highly homologous proteins, cyclin D1, D2, and D3. These pro-
teins are expressed in an overlapping fashion in all proliferating
cell types (Musgrove et al., 2011). D-cyclins bind and activate
Cdk4 and Cdk6, resulting in phosphorylation of the retinoblas-
toma protein pRB, as well as of the related p107 and p130 pro-
teins. pRB phosphorylation causes derepression and activation
of pRB-bound E2F transcription factors, which promote cell
cycle progression and DNA synthesis (S phase) (Sherr and Rob-
erts, 2004).
Consistent with their growth-promoting functions, overex-
pression of D-type cyclins plays a causative role in development
of a large number of human cancers. In several instances cyclin
D-overexpression is driven by gene amplifications or transloca-
tions. Indeed, the gene encoding cyclin D1 represents the
second most frequently amplified locus in the human cancer
genome (Beroukhim et al., 2010). Also, genes encoding cyclins
D2 and D3 are frequently amplified or rearranged in human can-
cers (Deshpande et al., 2005). Moreover, several human cancers
overexpress particular cyclin D proteins without detectable ge-
netic alterations (Diehl, 2002).
Analyses of knockout mice lacking D-type cyclins and their
catalytic partners, Cdk4 and Cdk6, provided extensive genetic
evidence for the role of cyclin D-Cdk4/6 complexes in driving
cell proliferation. Thus, mice lacking cyclins D1, D2, D3, Cdk4,
or Cdk6 displayed proliferative deficiencies in specific cell com-
partments (for review, see Sherr and Roberts, 2004). Combined
ablation of all three D-type cyclins resulted in an embryonic
lethality of cyclin D1/D2/D3/ mice, due to a block in pro-
liferation of fetal liver hematopoietic cells (Kozar et al., 2004).
These results were recapitulated in mice lacking Cdk4 and
Cdk6, which also displayed severe proliferative failure in this
compartment (Malumbres et al., 2004). Hence, analyses of
knockout animals firmly established the function for D-cyclins
in driving cell proliferation in vivo.
The embryonic lethality of cyclin D1/D2/D3/ mice
restricted analyses of the function of all three D-cyclins in vivomental Cell 30, 255–267, August 11, 2014 ª2014 Elsevier Inc. 255
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vent this lethality by generating conditional cyclin D triple-
knockout mice. Using these mice, we studied the consequence
of an acute ablation of all three D-cyclins in the bone marrow of
adult mice. Unexpectedly, shut down of D-cyclins led to exten-
sive apoptosis of all hematopoietic cell types. We found that
adult hematopoietic stem cells are particularly dependent on
D-cyclins for survival and they are especially sensitive to cyclin
D loss. Ourmechanistic analyses revealed that D-cyclins repress
the expression of the death receptor, Fas and its ligand, FasL.
These findings provide a mechanism linking a cyclin protein to
cell survival in normal homeostasis in vivo.
RESULTS
Generation of Conditional ‘‘Triple-Knockout’’ Cyclin
D1F/FD2–/–D3F/F Mice
In order to address the requirement for cyclin D function in adult
mice, we interbred cyclin D1F/F and D3F/F conditional knockout
mice (Choi et al., 2012) with cyclin D2/ animals. The latter
strain develops normally, except for gonadal hypoplasia (Sicinski
et al., 1996). After a few rounds of crosses, we generated condi-
tional ‘‘triple-knockout’’ cyclin D1F/FD2/D3F/F (TKO) mice (Fig-
ure S1A available online). These animals are viable, consistent
with the expectation that the ‘‘floxed’’ cyclin D alleles are func-
tionally wild-type.
Acute Ablation of D-Cyclins in Adult Bone Marrow
We previously found that D-cyclins are essential for embryonic
hematopoiesis. Specifically, ablation of all three D-cyclins
blocked rapid expansion of embryonic hematopoietic stem/pro-
genitor cells, which takes place in fetal livers during mid-gesta-
tion. Consequently, cyclin D1/D2/D3/ mice died during
embryogenesis due to a severe anemia (Kozar et al., 2004).
Outside hematopoiesis, other cell types seemed to be unaf-
fected by cyclin D-loss, indicating that most embryonic cell
types can proliferate without D-cyclins (Kozar et al., 2004).
In the current study, we decided to test the requirement for
D-cyclins in adult hematopoiesis, which mostly takes place in
the bone marrow. The hematopoietic system is hierarchically
organized with the hematopoietic stem cell (HSC) at the apex.
This defined hierarchy of hematopoietic stem cells, progenitors,
and lineage-committed cell types, combined with our ability toFigure 1. Consequences of Cyclin D Ablation in Hematopoietic Cells
(A) Survival of Mx-Cre+;D1F/FD2/D3F/F (MxTKO) and control Mx-Cre+;D1F/+D
D-cyclins in MxTKO mice) (n = 23 per group). Day 0 corresponds to the first inje
(B) Representative images of Wright-Giemsa stained peripheral blood smears at
(C and D) Mean numbers of red blood cells (RBC), platelets (PLT), white blood ce
MxTKO versus MxCntrl mice (n = 5 per genotype). Error bars represent SD.
(E) Images of hematoxylin and eosin stained bone marrow sections. Note that nu
(F) Mean numbers of nucleated bone marrow cells per femur (n = 5 per genotyp
(G) Mean numbers of Gr1+ CD11b+ (myeloid), Ter119+ (erythroid), B220+ (B-lymp
bars represent SD.
(H) Bone marrow cells from MxTKO and MxCntrl mice were collected 5 days a
numbers of resulting colonies, scored after 12 days, from n = 3 biological replica
(I) Results of noncompetitive bone marrow reconstitution. Wild-type lethally irradia
the survival curve following pI-pC treatment (n = 4 per group). Note that deletion o
seen in intact MxTKO mice (panel A).
See also Figure S1.
Developisolate these cells based on surfacemarkers, allowed us to study
the requirement for D-cyclins in stem/progenitor cells as well as
at later stages of hematopoiesis.
To ablate D-cyclins in adult bone marrow, we intercrossed
TKO mice with Mx1-Cre animals. The latter strain expresses
inducible Cre recombinase in hematopoietic cells. Administra-
tion of polyI-polyC (pI-pC) to Mx1-Cre animals activates Cre
leading to deletion of the ‘floxed’ sequences in bone marrow
cells, including very efficient deletion in hematopoietic stem cells
(Ku¨hn et al., 1995). We verified that Cre recombinase was ex-
pressed at the same levels in bone marrows of control Mx-Cre+;
D1F/+D2+/D3F/+ (MxCntrl) and experimental Mx-Cre+;D1F/F
D2/D3F/F (MxTKO) animals (Figure S1B) and that pI-pC admin-
istration led to an efficient deletion of the floxed cyclin genes in
hematopoietic cells (Figure S1C).
Acute ablation of all three D-cyclins in bone marrows of
MxTKO mice resulted in 100% lethality within 11 days following
pI-pC administration (Figure 1A). Moribund MxTKO mice devel-
oped severe pancytopenia, as evidenced by a 7-fold reduction in
red blood cell counts and a 6-fold decrease in the number of
white blood cells (Figures 1B–1D).
Histopathological analyses of the bone marrows revealed that
nearly all nucleated cells were lost in MxTKO animals (Figures
1E–1G and S1D). This loss encompassed all lineages including
myeloid (Gr1+,CD11b+), erythroid (Ter119+), lymphoid B cells
(B220+), and T cells (CD3+) (Figure 1G). Consistent with these
findings, MxTKO bonemarrowwas devoid of any colony forming
units, as judged by methylcellulose assays (Figure 1H). The
disappearance of hematopoietic cells following an acute shut-
down of D-cyclins suggested that ablation of D-cyclins might
have triggered cell death of all bone marrow cells.
To determine whether the loss of bone marrow cells was
caused by an intrinsic defect in hematopoietic cells, we per-
formed bone marrow transplantation experiments (Fleming
et al., 2008). Wild-type recipient mice received a lethal dose of
irradiation, which ablated their own bone marrow, and then
were reconstituted with undeleted MxTKO bone marrow cells.
Following reconstitution, wild-type recipients were treated with
pI-pC, thereby deleting D-cyclins exclusively in the engrafted
hematopoietic cells. This led to a disappearance of bone
marrow cells and to death of the animals (Figure 1I), recapitu-
lating the effect seen in intact MxTKO mice (Figure 1A). Collec-
tively, these analyses revealed that the D-cyclins play a cell2+/D3F/+(MxCntrl) animals injected one to three times with pI-pC (to delete
ction.
day 8 postinjection.
lls (WBC), lymphocytes (LYM), and neutrophils (NEU) in the peripheral blood of
cleated bone marrow cells are virtually absent in an MxTKO animal.
e). Error bars represent SD.
hoid), and CD3+ (T-lymphoid) cells in bone marrow (n = 5 per genotype). Error
fter ablation of D-cyclins and plated in methylcellulose. Shown are the mean
tes. Error bars represent SD.
ted mice received either undeleted MxTKO or MxCntrl bone marrow. Shown is
f D-cyclins following bone marrow reconstitution recapitulated the phenotype
mental Cell 30, 255–267, August 11, 2014 ª2014 Elsevier Inc. 257
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etic cells.
Rapid Apoptosis of Hematopoietic Stem Cells following
Ablation of D-Cyclins
To gauge the response of hematopoietic stem cells to cyclin D
shutdown, we investigated early time points following ablation
of D-cyclins, when the total numbers of bone marrow cells
have not yet been impacted. We treated animals with a single
dose of pI-pC, collected bone marrow cells after 12, 48, and
96 hr and stained them with surface markers for hematopoietic
stem cells (Linlow c-kit+ Sca+ CD48 CD150+, further called
HSC). We then used flow cytometry to quantify HSC numbers
at different time points after cyclin D shutdown (Figure 2A). Strik-
ingly, we observed that50%of stem cells disappeared as early
as 12 hr after ablation of D-cyclins (Figure 2B), while the number
of more mature bone marrow cells remained unchanged at this
time point (Figure 2C). Essentially 100% of stem cells disap-
peared within 48 hr (Figure 2B), a time point when more mature
bone marrow cells displayed a slight, but statistically nonsignif-
icant drop in cell numbers (Figure 2C). At 96 hr, the HSC were
essentially undetectable (Figures 2B and 2D), while the numbers
of more mature bone marrow cells were reduced by 50% (Fig-
ure 2C). These observations suggested that HSC are particularly
dependent on D-cyclins for their survival, as they are especially
sensitive to cyclin D ablation.
Ablation of D-Cyclins Leads to Apoptosis of Quiescent
Stem/Progenitor Cells
Unlike embryonic hematopoietic stem cells, which are rapidly
proliferating, adult bone marrow hematopoietic stem cells repre-
sent a largely nondividing, quiescent cell population (Wilson
et al., 2008). On the other hand, D-cyclins are believed to be ex-
pressed in proliferating cells where they govern G1 phase pro-
gression (Sherr and Roberts, 2004). Intrigued by the loss of
HSC following shutdown of D-cyclins, we flow sorted HSC
from intact wild-type animals and determined that these cells ex-
press all three D-type cyclins (Figure S2A). We next injected
MxTKO and MxCntrl mice with a single pI-pC dose and evalu-
ated whether quiescent hematopoietic stem/progenitor cells
(lineage-negative, c-Kit+ and Sca+, further called HSPC) undergo
apoptosis upon acute ablation of D-cyclins. Quiescent (G0)
HSPC cells were identified by means of Ki67 and DAPI staining,
the standard procedure used to analyze quiescent stem cells
(Gurumurthy et al., 2010; Wilson et al., 2008; Rossi et al.,
2007). Staining of these cells for cleaved caspase 3 revealed
wide-spread apoptosis of quiescent HSPC following ablation
of D-cyclins (Figures 2E and 2F). In contrast, essentially no
apoptosis was detected among HSPC of control animals, which
were treated in the same way (Figures 2E and 2F). These obser-
vations indicated that D-cyclins play a rate-limiting, prosurvival
function in quiescent hematopoietic stem/progenitor cells.
Apoptosis of All Bone Marrow Cells after Shutdown of
D-Cyclins
Analyses of bone marrow cells at later time points indicated that
eventually all hematopoietic cells underwent apoptosis following
shutdown of D-cyclins, explaining the lethality seen in triple
knockout animals. Within the whole bone marrow cell popula-258 Developmental Cell 30, 255–267, August 11, 2014 ª2014 Elsevietion, an increased apoptotic rate was first detected at 96 hr (Fig-
ure 3A), and by 6 days the majority of bone marrow cells were
TUNEL positive (Figures 3B and 3C). These results indicate
that all adult hematopoietic cells depend on D-cyclins for
survival.
Given this widespread apoptosis of bone marrow cells, we
asked whether blocking the apoptotic process might at least
partially rescue the phenotype of cyclin D shutdown. Because
activation of caspases represents a central step in the execution
of apoptosis (Strasser et al., 2009), we attempted to block this
step by administering an irreversible broad-spectrum caspase
inhibitor, QVD-OPh (Caserta et al., 2003) to MxTKO animals
concomitantly with ablation of D-cyclins. Inhibition of caspase
activation significantly reduced the extent of bone marrow cell
apoptosis following D-cyclin ablation (Figures 3D–3G) and
partially protected against the loss of bone marrow cells (Figures
3D and S2B).
It should be noted that in addition to the apoptotic response,
ablation of D-cyclins blocked proliferation of bone marrow cells
(Figures S2C and S2D). For this reason, inhibition of the
apoptotic process only partially rescued the phenotype of cyclin
D-deficiency, as cell cycle arrest was still in place followingQVD-
OPh treatment (Figures S2E and S2F). Collectively, these ana-
lyses established caspase-dependent hematopoietic cell death
as a mechanism of the loss of bone marrow cells following abla-
tion of D-cyclins.
D-Cyclins Regulate Apoptosis through Fas and FasL
In order to gain mechanistic insights into the pro-survival func-
tion of D-cyclins in hematopoietic cells, we evaluated the tran-
scriptional changes in bone marrow cells following an acute
ablation of D-cyclins. We focused our analysis on 84 key
apoptosis-relevant genes, using an RT-PCR-based apoptosis
PCR array (Figure 4A). Transcripts of eight genes were consis-
tently upregulated upon cyclin D shutdown in bone marrow cells
(Figures 4B and 4C; Table S1). Two of these genes encode pro-
apoptotic proteins, which function within the same pathway to
induce cell death: the death receptor Fas and its ligand, FasL
(Strasser et al., 2009). We confirmed upregulation of the Fas pro-
tein as well as increased cell surface expression of both Fas and
FasL in cyclin D-deleted hematopoietic cells (Figures 5A and 5B).
We also confirmed upregulation of Fas and FasL transcripts in
hematopoietic stem/progenitor cells in vivo following ablation
of D-cyclins (Figure 5C).
Interaction of the death receptor Fas with its ligand, FasL trig-
gers cell death via an extrinsic apoptotic process that involves
activation of caspase 8 (Strasser et al., 2009). Indeed, we
observed activation of caspase 8 following cyclin D deletion in
hematopoietic cells (Figures 5D and 5E). At these early time
points we detected no changes in mitochondrial membrane po-
tential (Figure S3A). However, at later times, changes in mito-
chondrial membrane potential were observed (Figure S3A),
consistent with the fact that the extrinsic pathway may lead to
mitochondrial activation (Strasser et al., 2009). Collectively,
these observations indicate that ablation of D-cyclins leads to
upregulation of Fas and FasL and triggers the Fas/FasL/ cas-
pase 8 apoptotic pathway in hematopoietic cells.
To further substantiate upregulation of Fas and FasL as the
cause of apoptosis of hematopoietic cells, we asked whetherr Inc.
Figure 2. Apoptosis of Hematopoietic Stem/Progenitor Cells following Shutdown of D-Cyclins
(A) Outline of the experimental design. Mx-Cre+;D1F/FD2/D3F/F (MxTKO) and control Mx-Cre+;D1F/+D2+/D3F/+(MxCntrl) animals received a single injection of
pI-pC (to delete D-cyclins in MxTKO mice). Animals were sacrificed after 12, 48, and 96 hr, and hematopoietic stem cells (HSC) were stained and quantified
by FACS.
(B and C) Mean number of HSC (B) and mean number of total bone marrow cells (C) per animal (including femurs, tibias, iliac crests, and humeruses) at the
indicated time points after ablation of D-cyclins. Error bars represent SD.
(D) Representative FACS analysis of HSC (Linlow, c-Kit+, Sca1+, CD48-, CD150+) from bone marrows collected at 96 hr after deletion of D-cyclins. Note that
essentially no HSC were detected in MxTKO animals.
(E) Twenty-four to 48 hr after ablation of D-cyclins, hematopoietic stem/progenitor cells (HSPC)were stainedwith DAPI (40,6-diamidino-2-phenylindole), Ki67, and
cleaved caspase 3 (to mark apoptotic cells). HSPC then were gated on G0 cells (Wilson et al., 2008) and analyzed for cleaved caspase 3 staining.
(F) The mean percentage of caspase 3-positive cells among quiescent HSPC cells, gated as above, in MxCntrl and MxTKO animals. Error bars represent SD.
See also Figure S2.
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Figure 3. Apoptosis of Bone Marrow Cells after Ablation of D-Cyclins
(A and B) Mean percentage of Annexin V+ (apoptotic) bone marrow cells in MxTKO and MxCntrl mice (n = 5 per genotype), at 48 and 96 hr after ablation of
D-cyclins. Error bars represent SD.
(B) Staining of femur sections for apoptotic cells (TUNEL). Cells were counterstained with methyl green. Note strongly increased number of apoptotic cells
(TUNEL+) and paucity of viable nucleated cells (TUNEL/methyl green+) in MxTKO bone marrow.
(C) Mean percentages of TUNEL-positive bonemarrow cells analyzed by FACS 4–6 days after ablation of D-cyclins (MxTKO). Each dot corresponds to a different
animal (n = 7 mice per group), horizontal lines denote mean values.
(D–G) MxTKO and MxCntrl mice were injected with caspase inhibitor QVD-OPh (CI), with vehicle only (DMSO), concomitantly with the deletion of D-cyclins, and
bone marrows were collected 6 days later.
(legend continued on next page)
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Figure 4. Molecular Analyses of Hematopoietic Cells after Cyclin D Shutdown
(A) Strategy for the identification of genes with altered expression upon ablation of D-cyclins. Bonemarrows fromMxTKO andMxCntrl mice (n = 4 per group) were
collected 48 hr after one dose of pI-pC (to delete D-cyclins in MxTKO mice) and analyzed for the expression levels of apoptotic genes by RT-PCR-based array
(see Supplemental Experimental Procedures).
(B) Volcano plot analysis using web-based software for Apoptosis RT2 Profiler Apoptosis PCR SArray PAMM-3012 (QIAGEN) for four biological replicates from
MxTKO and MxCntrl mice. The volcano plot displays significance of changes (Log10 p values) versus fold-change (Log2 fold change TKO/Cntrl) on the y and x
axes, respectively. Eight genes encircled in red satisfied the following criteria: (1) genes that had >2-fold increased (red vertical line) or decreased (blue vertical
line) expression in MxTKO, as compared to MxCntrl, and (2) the significance of changes had a p value <0.05 (thin horizontal line).
(C) Results of RT-PCR analysis for eight genes that were identified by Apoptosis PCR Array as having altered expression (>2 fold change, p < 0.05) in cyclin
D-deleted bone marrows. Each dot shows the fold-change expression in MxTKO versus MxCntrl bone marrows, for each of the four independent biological
replicates. Horizontal lines denote mean fold-change for the indicated genes, red dashed line = no change (ratio of 1).
See also Table S1.
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D shutdown. To address this question, we injected MxTKOmice
with anti-FasL neutralizing antibody (or with isotype-matched
IgG, as a control) concomitantly with deletion of D-cyclins. Sub-
sequently, the in vivo apoptotic rate of hematopoietic stem cells
and hematopoietic stem/progenitor cells was examined by
Annexin V staining. Strikingly, inhibition of Fas signaling blocked(D) Shown are representative images of hematoxylin and eosin stained sections
bone marrow cells (MxTKO-DMSO, upper right panel), and treatment with caspa
(E) TUNEL staining of femur sections to detect apoptotic cells. Cells were counters
(CI) decreased the fraction of apoptotic cells in MxTKO mice (lower right panel) a
(F) Representative FACS profiles of bone marrow cells stained with TUNEL (to de
analyzed by FACS. The percentages of apoptotic (TUNEL+) cells are marked. N
(MxTKO-DMSO versus MxTKO-CI). Also note that ablation of D-cyclins reduced
cells, which is indicative of cell cycle arrest (see also Figures S2C–S2F).
(G) Percentages of TUNEL+ cells in bone marrows of MxTKO and MxCntrl mice t
quantified by FACS. Each dot corresponds to a different animal (n = 5 for each g
See also Figure S2.
Developapoptosis of HSC and HSPC triggered by cyclin D shutdown
(MxTKO-aFasL, Figures 5F and 5G). We also confirmed that
anti-FasL antibody blocked death of unsorted bonemarrow cells
(data not shown). These analyses point to upregulation of Fas
signaling as a cause of death of all hematopoietic cells, including
stem cells, upon ablation of D-cyclins. On the other hand, we did
not detect upregulation of p53 transcriptional targets Bax, Noxaof bone marrows. Note that ablation of D-cyclins resulted in loss of nucleated
se inhibitor partially rescued this effect (MxTKO-CI, lower right panel).
tained withmethyl green. Note that treatment of animals with caspase inhibitor
nd increased the number of nucleated cells.
tect apoptotic cells) and with propidium iodide (PI, for cell cycle analysis) and
ote that treatment with CI blocked apoptosis triggered by cyclin D ablation
the fraction of cells with >2N DNA content and increased the proportion of 2N
reated with DMSO or with caspase inhibitor QVD-OPh (CI). TUNEL+ cells were
roup), horizontal lines represent mean values.
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Figure 5. Fas/FasL Signaling Is a Critical Mediator of Apoptosis Induced by Cyclin D Ablation
(A) FACS analysis of Fas and FasL surface expression in MxTKO and MxCntrl bone marrow cells 2 days after ablation of D-cyclins (MxTKO). Note increased
staining in MxTKO as compared to MxCntrl.
(B) Western blot analysis of Fas protein levels in bone marrow 2 days after ablation of D-cyclins (MxTKO).
(C) Upregulation of Fas and FasL mRNA levels in hematopoietic stem/progenitor cells (HSPC) 24 hr after ablation of D-cyclins (MxTKO). N = 4 mice for each
genotype, error bars represent SD.
(D) Intracellular staining for cleaved caspase 8 in bone marrow cells 2 days after cyclin D-deletion (MxTKO). Note increased staining in MxTKO as compared to
MxCntrl.
(E) Western blot analysis of the levels of cleaved caspase 8 in bone marrow cells of MxCntrl and MxTKO mice, 3 days after pI-pC injection (to delete D-cyclins in
MxTKO).
(F and G) MxTKO and MxCntrl mice were injected with neutralizing anti-FasL antibody (aFasL), or with isotype control (IgG) concomitantly with administration of
pI-pC (to delete D-cyclins inMxTKOmice). Two days later, hematopoietic stem/progenitor cells, HSPC (F), or hematopoietic stem cells, HSC (G) were flow-sorted
and stained with Annexin V and 7AAD to mark apoptotic (Annexin V+/7AAD+) cells. Note that inhibition of FasL abrogated apoptosis of HSC and HSPC triggered
by ablation of D-cyclins (compare MxTKO-IgG versus MxTKO-aFasL). (F) Shows representative staining with Annexin V and 7AAD. (G) Mean percentage of
Annexin V+ HSC (n = 3 mice for MxCntrl and n = 5 MxTKO). Error bars represent SD.
See also Figure S3.
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not shown), suggesting that these pathways do not play a
major role in hematopoietic cell death following shutdown of
D-cyclins.
Collectively, our findings suggest a model in which D-cyclins
repress the expression of Fas and FasL in hematopoietic cells.
Ablation of D-cyclins leads to upregulation of these proteins
and triggers caspase 8-initiated apoptosis.
D-Cyclins Repress Expression of Fas and FasL via E2F1
In order to understand how D-cyclins regulate the expression
of Fas and FasL in bone marrow cells, we focused on the
pRB/ E2F pathway. It is well established that D-cyclins control
the activity of E2F transcription factors by phosphorylating pRB;
pRB phosphorylation results in release or derepression of E2F
transcriptional activity (Trimarchi and Lees, 2002; Sherr and
Roberts, 2004). Consistent with this model, we observed that
ablation of D-type cyclins in bone marrow cells strongly
decreased pRB phosphorylation (Figures S4A and S4B), leading
to reduced levels of E2F transcriptional targets (Figure S4C). The
E2F1 gene represents an established E2F target (Neuman et al.,
1994) and its expression was strongly reduced in total bone
marrow and in hematopoietic stem cells upon cyclin D shutdown
(Figures 6A and 6B). Moreover, the E2F1 protein was virtually un-
detectable in bone marrow cells following acute cyclin D shut-
down (Figure 6C). In contrast, the levels of E2F2 and E2F3
were not affected (Figures 6A and 6C).
Genetic ablation of E2Fs1-3 was shown to result in apoptosis
of several compartments, including bonemarrow cells, revealing
that E2Fs play prosurvival roles in vivo (Chen et al., 2009; Chong
et al., 2009; Trikha et al., 2011). Therefore, we asked whether an
acute loss of E2F1 upon cyclin D ablation might be responsible
for upregulation of the Fas and FasL transcripts. To address
this, we first knocked down E2F1 in hematopoietic cells (Figures
S5A–S5C). We observed that this led to increased expression of
the endogenous Fas and FasL transcripts (Figure 6D) and was
sufficient to trigger apoptosis of hematopoietic cells (Figures
6E–6G). Importantly, treatment of hematopoietic cells with an
anti-FasL neutralizing antibody inhibited apoptosis triggered by
E2F1 knockdown (Figure S5D).
To establish a direct link between E2F1 and Fas/FasL
expression, we utilized promoters of these two genes in pro-
moter-reporter assays and gauged their activity in the presence
of ectopically expressed E2F1, E2F2, or E2F3. We observed
that ectopic expression of E2F1 repressed activity of Fas and
FasL promoters, whereas E2F2 or E2F3 did not have a repres-
sive effect (Figures 6H and S5E). We next flow-sorted he-
matopoietic stem/progenitor cells from wild-type mice and
examined the association of the endogenous E2F1 with the
Fas gene promoter using chromatin immunoprecipitation
(ChIP). We observed that E2F1 physically associates with the
Fas promoter in HSPC (Figures 6I and S5F). Moreover, deletion
of the E2F1-binding region (defined by the ChIP analysis) from
the Fas promoter abrogated the repressive effect of E2F1 in
promoter-reporter assays (Figures S5G and S5H). Furthermore,
the effect of E2F1 on the wild-type Fas promoter was essen-
tially lost when E2F1 DNA nonbinding and transactivation-
deficient mutant (Hsieh et al., 1997) was used in these assays
(Figure S5G).DevelopCollectively, our findings suggest that the cyclin D/ E2F1/
Fas signaling axis represents an important regulatory pathway of
the apoptotic machinery in vivo (Figure 7). In hematopoietic cells,
E2F1 physically binds the promoter of Fas (and likely FasL)
genes and represses their expression. Ablation of D-cyclins
causes strong reduction of E2F1 levels and results in derepres-
sion of the Fas and FasL genes. This leads to upregulation of
Fas and FasL proteins and triggers ‘‘extrinsic,’’ caspase
8-dependent apoptosis. Consistent with this model, inhibition
of Fas/FasL signaling protects hematopoietic cells from
apoptosis triggered by cyclin D-ablation, while knockdown of
E2F1 causes upregulation of Fas/FasL and induces apoptosis
despite the continued expression of D-cyclins.
DISCUSSION
D-type cyclins represent components of the ancestral core cell
cycle machinery that has been conserved from yeast to humans.
It is well established that the major function of D-cyclins is to
drive cell proliferation. This notion is supported by overwhelming
evidence revealing that germline ablation of D-cyclins, or knock-
down of D-cyclins in cancer cells, ectopic expression of cyclin
D-Cdk4/6 inhibitor p16INK4a, or treatment of cells with a chemical
inhibitor of cyclin D-associated kinase, all resulted in cell-cycle
arrest (Fry et al., 2004; Lukas et al., 1995; Sherr and Roberts,
2004).
It has recently become increasingly clear, however, that the
function of cyclin D-Cdk4/6 complexes is not restricted to regu-
lation of the cell cycle, and that the consequences of inhibition of
these complexes extend beyond a transient cell-cycle arrest
(Choi and Sicinski, 2013). For instance, D-cyclins, together
with their catalytic partner proteins, Cdk4 and Cdk6, are power-
ful suppressors of cellular senescence (Zou et al., 2002; Ruas
et al., 2007; Puyol et al., 2010; Anders et al., 2011).
In order to delineate the in vivo functions of D-cyclins in an
adult organism, in this study we examined the consequences
of an acute shutdown of all three D-cyclins in bone marrow cells
of adult mice. We focused on this compartment, because our
previous work revealed that during embryogenesis D-cyclins
are essential for proliferation of hematopoietic stem/progenitor
cells (Kozar et al., 2004). Thus, constitutive, germline ablation
of all three D-type cyclins resulted in a proliferative block in em-
bryonic liver hematopoietic stem/progenitor cells, consistent
with the well-established function for D-cyclins in driving cell
proliferation (Kozar et al., 2004). Unexpectedly, we now ob-
served that ablation of D-cyclins in hematopoietic cells of adult
mice triggered apoptosis. All hematopoietic cells died after shut-
down of D-cyclins, indicating that D-cyclins are required for sur-
vival of all bone marrow cell types. Importantly, we found that
adult hematopoietic stem cells are particularly sensitive to cyclin
D loss, as apoptosis occurred first in this compartments. These
findings reveal that D-cyclins play a previously unanticipated
major prosurvival function in the cells of adult organisms.
It remains to be seen why D-cyclins play a prosurvival role in
adult bone marrow cells, but not in embryonic cells. One possi-
bility is that in adult hematopoietic cells E2F1 transcription factor
plays a rate-limiting role in repressing Fas and FasL expression,
whereas in embryonic cells Fas/FasL genes are repressed by
additional mechanism(s). Consequently, ablation of D-cyclins,mental Cell 30, 255–267, August 11, 2014 ª2014 Elsevier Inc. 263
(legend on next page)
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Figure 7. A Proposed Model Explaining a Prosurvival Function of
D-Cyclins in Hematopoietic Cells via a Cyclin D / E2F / Fas/
FasL Pathway
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apoptosis in adult hematopoietic cells but not in cells of a devel-
oping embryo.
It was originally reported, based largely on in vitro cell culture
systems, that E2Fs1–3 act as activators of transcription and can
induce proapoptotic genes when overexpressed (for review, see
DeGregori and Johnson, 2006; Iaquinta and Lees, 2007). How-Figure 6. D-Cyclins Repress Expression of Fas and FasL via E2F1
(A) Relative expression of E2F1, E2F2, and E2F3 transcripts in bonemarrow cells 4
(B) Relative expression of E2F1 transcripts in hematopoietic stem cells (HSC) 24 h
represent SD.
(C) Protein levels of E2F1, E2F2, and E2F3 in bone marrow cells 48 hr following
(D–G) Bone marrow cells were transduced with viruses encoding anti-E2F1 shRN
did not undergo any selection after viral transduction. Therefore, E2F1 knockdow
underestimate the effects of E2F1 depletion. See also Figure S5A.
(D) Results of RT-PCR analysis for the levels of the endogenous Fas and FasL tr
(E–G) Mean percentages of cleaved caspase-3-positive cells (E), trypan blue-pos
following knock-down of E2F1. Error bars represent SD.
(H) Fas and FasL promoter-luciferase constructs were cotransfected with vecto
expression significantly reduced transcription from both Fas and FasL promoter
(I) Chromatin immunoprecipitation (ChIP) studies of E2F1 binding to the Fas promo
both anti-E2F1 antibodies used (Santa Cruz, bright red; Millipore, dark red). Data
control region away from the Fas promoter. Below, a schematic representation o
See also Figures S4 and S5.
Developever, genetic experiments from the Leone (Chong et al., 2009)
and Bremner (Chen et al., 2009) groups revealed that E2Fs1–3
can function in mouse development as transcriptional repres-
sors. Thus, conditional ablation of E2Fs1–3 in retinas, intestine,
and in bone marrow resulted in an increased apoptotic rate,
although not as wide-spread as the one described here upon
cyclin D loss (Chen et al., 2009; Chong et al., 2009; Trikha
et al., 2011). In the context of retinas, the apoptosis was caused
by altered expression of an E2F target, Sirt1 (Chen et al., 2009).
However, Sirt1 expression was not affected by ablation of D-
cyclins in bone marrow cells of MxTKO mice (data not shown).
Trikha et al. (2011) used MxCre mice to delete E2Fs1–3 in
bone marrow cells and observed increased apoptosis in the
myeloid cells. The authors did not report the molecular basis of
this phenomenon, but observed that E2Fs1–3 act in this lineage
as transcriptional repressors. It should be noted that Trikha et al.
(2011) used constitutive E2F1 knockout mice that could have
masked the full effect of a sudden E2F1 loss due to possible
compensatory mechanisms.
Our study suggests a model that in adult hematopoietic cells
D-cyclins inhibit apoptosis by maintaining levels of E2F1, which
represses the death receptor Fas and its ligand, FasL (Figure 7).
Cellular apoptosis can be mediated by two distinct pathways:
an ‘‘extrinsic’’ pathway triggered by the engagement of the
death receptor, which involves activation of caspase 8, and an
‘‘intrinsic’’ pathway propelled by mitochondrial damage, which
causes release of cytochrome c and activation of caspase 9
(Strasser et al., 2009). Our study revealed that D-cyclins control
the extrinsic pathway, as evidenced by Fas-mediated activation
of caspase 8 upon cyclin D ablation, the lack of mitochondrial
involvement at early stages of apoptosis, and by the ability of
anti-FasL antibodies to block apoptosis of hematopoietic cells.
It will be interesting to determine whether breeding of cyclin D
TKO animals into Fas null background (Adachi et al., 1995) would
rescue at least some phenotypic manifestations of cyclin
D-deficiency.
One of the most unexpected findings from our study is the
observation that D-cyclins play a prosurvival function also in
quiescent hematopoietic stem/progenitor cells. According to
the current understanding, D-cyclins are expressed and function
in proliferating cells. However, we demonstrated that quiescent
hematopoietic stem cells express D-cyclins and that D-cyclins8 hr following an acute ablation of D-cyclins (MxTKO). Error bars represent SD.
r after ablation of D-cyclins (MxTKO). N = 3 mice for each genotype. Error bars
acute ablation of D-cyclins (MxTKO).
A (shE2F1), or with control shRNA (shCtrl). Please note that bone marrow cells
n took place only in a fraction of cells and hence the observed changes likely
anscripts.
itive dead cells (F), and mean total number of remaining bone marrow cells (G),
rs encoding E2F1, E2F2, E2F3, or with an empty vector (EV). Note that E2F1
s (see also Figures S5E and S5G). Error bars represent SD.
ter in HSPC. Binding of E2F1 to a region of the Fas promoter was observedwith
represent mean ± SEM of three replicates. Negative control region (NCR) is a
f the Fas promoter. Error bars represent SD.
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paucity of hematopoietic stem cells precludes detailed mecha-
nistic analyses specifically in this cell type.
The work presented in this study revealed an unexpected anti-
apoptotic function of critical cell-cycle proteins. The functional
significance of our findings is highlighted by the observation
that widespread apoptosis represented a major consequence
of cyclin D ablation in the bone marrow of adult animals. These
analyses reveal that D-cyclins play a particularly important role
in maintaining cellular mass, both by driving cell division and
by acting as essential, rate-limiting regulators of cell survival.
EXPERIMENTAL PROCEDURES
Generation of Triple-Knockout Cyclin D1F/FD2–/–D3F/F Mice and
Ablation of D-Cyclins in Bone Marrow
Genotyping of cyclin D triple-knockout mice is described in the Supplemental
Experimental Procedures. These animals were crossed with Mx1-Cre mice
(from Jackson Laboratory). To delete D-cyclins in hematopoietic cells, 6-to
10-week-old Mx1-Cre+;D1F/FD2/D3F/F (MxTKO) and control Mx1-Cre+;
D1F/+D2+/D3F/+ animals were injected intraperitoneally, one to five times on
alternate days, with 2.5 mg/g body weight of polyinosinic-polycytidylic acid
(pI-pC, Amersham).
Histological Analyses and In Vivo BrdU Incorporation Assay
Paraffin-embedded 5 mm thick sections were stained with Wright-Giemsa, he-
matoxylin and eosin, BrdU, or TUNEL as described below. For BrdU incorpo-
ration, mice were injected intraperitoneally with 1 mg of BrdU and sacrificed
after 2 hr. Bone marrow cells were harvested, assayed with BrdU-Flow kit
(BD Biosciences),and analyzed by FACS.
Apoptosis Assays
The apoptotic rate was quantified by TUNEL staining using in situ cell death kit
(Roche) or by FACS analysis using ApoBrdU kit (Phoenix Flow Systems).
Cleaved caspase 3 and cleaved caspase 8 were quantified by intracellular
staining (CaspGlow 3 or CaspGlow 8 kits from Biovision). To gauge apoptosis
of HSC or HSPC, cells were stained with Annexin V-FITC and 7AAD (BD
Biosciences) and analyzed by FACS.
Flow Cytometry, Hematological Analyses, and Bone Marrow
Reconstitution
Description of hematological and flow cytometric analyses, including staining
of HSC and HSPC (LKS), as well as noncompetitive marrow transplantation
assays are described in the Supplemental Experimental Procedures.
Knockdown of E2F1 in Bone Marrow Cells
Primary wild-type bone marrow cells were cultured in RPMI supplemented
with 10% heat-inactivated FBS (Hyclone), Pen/Strep (100 U/ml; Invitrogen),
mSCF (1 or 10 ng/ml), mIL-3 (10 ng/ml; Peprotech), and mIL-6 (10 ng/ml;
Peprotech) and infected with shE2F1 lentivirus (sc-35247, Santa Cruz) or
Scramble control lentivirus (sc-108080, Santa Cruz) and assayed for
knockdown of E2F1 using RT-PCR and nested PCR (sc-35247PR). Three
anti-E2F1 small hairpin RNA (shRNA) sequences were used: (1) 50-CGCTA
TGAAACCTCACTAATTCAAGAGATTAGTGAGGTTTCATAGCGTTTTT-30, (2)
50-CCAAGAAGTCCAAGAATCATTCAAGAGATGATTCTTGGACTTCTTGGTTT
TT-30, and (3) 50-GAAGGATGTTGTACAGTGTTTCAAGAGAACACTGTACAA
CATCCTTCTTTTT-30. In experiments shown in Figure S5D, 50 mg/ml of anti-
FasL neutralizing antibody (clone MFL3, BioLegend) or isotype control
Hamster IgG (clone HTK888, BioLegend) was added to the culture medium
contemporaneously with E2F1 knockdown.
QVD-OPh Caspase Inhibitor Rescue In Vivo
MxTKO and MxCntrl mice were injected once with pI-pC and twice with QVD-
OPh (irreversible broad-spectrum caspase inhibitor, 25 mg/kg body weight,
from Biovision) on days 0 and 3. On day 6, mice were sacrificed and bone266 Developmental Cell 30, 255–267, August 11, 2014 ª2014 Elseviemarrow sections were stained with hematoxylin and eosin or TUNEL. In addi-
tion, TUNEL staining was quantified by FACS.
Anti-FasL Neutralization In Vivo
MxTKO and MxCntrl mice were injected intraperitoneally once with pI-pC
plus one injection of either anti-FasL neutralizing antibody (clone MFL3,
BioLegend), or isotype control Hamster IgG (clone HTK888, BioLegend).
Mice were sacrificed 48 hr after treatment, and HSC and HSPC were analyzed
by Annexin V/7AAD staining.
Western Blotting and Fas/FasL Surface Staining
Whole cell extracts were prepared frombonemarrows and proteins solubilized
as described before, immunoblotted, and probed with antibodies against
cyclin D1 (Neomarker), cyclin D3 (C-16, Santa Cruz), E2F1 (Santa Cruz),
E2F2 (Santa Cruz), E2F3 (Santa Cruz), Fas (Millipore), Cre (Novagen), cleaved
caspase 8 (8592, Cell Signaling), tubulin (DM1A, Sigma), and hemagglutinin
(HA.11, Covance). For pRB phosphorylation analysis, cells were fixed, per-
meabilized, and stained with phycoerythrin (PE)-mouse antiphospho-
pRbS780 antibody (BD Biosciences) or isotype IgG1 control and analyzed
by FACS. For surface staining of bone marrow cells, anti-Fas-PE (BD Biosci-
ences) and anti-FasL-FITC or -PE (BioLegend) antibodies were used, followed
by FACS analysis.
Apoptosis Array and Gene Expression Analysis
Expression analyses of apoptotic target genes were conducted as described
in the Supplemental Experimental Procedures. The levels of Fas, FasL, E2F1,
E2F2 E2F3, Bax, Noxa, Puma, cyclin D1, D2, D3, E1, E2, and A2 transcripts
were quantified in total bone marrow, HSPC, and HSC by reverse-transcrip-
tion-quantitative PCR as described in the Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.devcel.2014.06.015.
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